# Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

> **NCT01876368** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 376 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Olmesartan
- **DRUG:** Placebo of LCZ696
- **DRUG:** Placebo of Olmesartan

## Key facts

- **NCT ID:** NCT01876368
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876368, "Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01876368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*